We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.
- Authors
Van Cutsem, E.; Danielewicz, I.; Saunders, M. P.; Pfeiffer, P.; Argilés, G.; Borg, C.; Glynne-Jones, R.; Punt, C. J. A.; Van de Wouw, A. J.; Fedyanin, M.; Stroyakovskiy, D.; Kroening, H.; Garcia-Alfonso, P.; Wasan, H.; Falcone, A.; Fougeray, R.; Egorov, A.; Amellal, N.; Moiseyenko, V.
- Abstract
Background: Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in the TASCO1 trial; here, we present the final overall survival (OS) results. Methods: TASCO1 was an open-label, non-comparative phase II trial. Patients (n = 153) were randomised 1:1 to TT-B (trifluridine/tipiracil 35 mg/m2 orally twice daily on days 1–5 and 8–12, and bevacizumab intravenously 5 mg/kg on days 1 and 15 of each 28-day cycle) or capecitabine plus bevacizumab (C-B; capecitabine, 1250 mg/m2 orally twice daily on days 1–14 and bevacizumab 7.5 mg/kg intravenously on day 1 of each 21-day cycle). Final OS was analysed when all patients had either died or withdrawn from the study. Adjusted multivariate regression was used to investigate the effects of pre-specified variables on OS. Results: At 1 September 2020, median OS was 22.3 months (95% CI: 18.0–23.7) with TT-B and 17.7 months (95% CI: 12.6–19.8) with C-B (adjusted HR 0.78; 95% CI: 0.55–1.10). No variables negatively affected OS with TT-B. Safety results were consistent with prior findings. Conclusions: TT-B is a promising therapeutic regimen in mCRC patients ineligible for intensive chemotherapy. Clinical trial information: NCT02743221 (clinicaltrials.gov)
- Publication
British Journal of Cancer, 2022, Vol 126, Issue 11, p1548
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/s41416-022-01737-2